Session » RA – Diagnosis, Manifestations, & Outcomes Poster II: Treatments, Outcomes, & Measures

Date: Monday, November 11, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1355

A Comparison of Clinical Improvement Following a Major Therapeutic Change Utilizing Updated Treatment Thresholds Defined by Three Different Disease Activity Measures

9:00AM-11:00AM: Abstract Number: 1354

A Comparison of Convergent Validity and Sensitivity to Change of the Conventional Scoring Method to Alternative Scoring Methods of the Health Assessment Questionnaire in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1347

Achievement of Remission in Two Early Rheumatoid Arthritis Cohorts Implementing Different Treat-To-Target Strategies

9:00AM-11:00AM: Abstract Number: 1364

Affect of Obesity on Multi-Biomarker Disease Activity (MBDA) Measurements in Rheumatoid Arthritis (RA) Patients

9:00AM-11:00AM: Abstract Number: 1367

An Engineered Glove for the Computerised Quantification of Hand Disability in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1369

Angiogenic Factors for Assessing Rheumatoid Arthritis in the Era of Sonographic Diagnosis and Biologic Therapy

9:00AM-11:00AM: Abstract Number: 1345

Are There Differences in Efficacy and Safety of Biological Disease-modifying Antirheumatic Drugs Between Elderly-onset and Young-onset Rheumatoid Arthritis?

9:00AM-11:00AM: Abstract Number: 1365

Construct Validation of PROMIS Short Form and Profile-29 T-Scores with SF-36 in Rheumatoid Arthritis Patients Treated for 1 Year: Results from a Real World Evidence-Based Study in the United States

9:00AM-11:00AM: Abstract Number: 1359

Correlation of Ultrasound Guided Synovial Biopsies and Surgical Synovial Biopsies in Patients with Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 1371

Create an Algorithm of Outcome Forecasting and Decision Making for RA Treatment: Data Mining and Machine Learning via the Smart System of Disease Management (SSDM)

9:00AM-11:00AM: Abstract Number: 1356

DAS28-CRP Cut-offs for High Disease Activity Assessment Is Lower Than DAS28-ESR in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1358

Defining Minimal Clinically Important Changes for the Patient Activity Scale-II

9:00AM-11:00AM: Abstract Number: 1349

Earlier Biologic Initiation over Two Decades of Real World Observational Data from the RAPPORT Biologics Registry of Northern Alberta, Canada

9:00AM-11:00AM: Abstract Number: 1352

Effects of Upadacitinib on Patient-Reported Outcomes After 24 Weeks in Patients with Active Rheumatoid Arthritis and an Inadequate Response to Conventional Synthetic or Biologic Disease-Modifying Anti-Rheumatic Drugs: Results from SELECT-NEXT and SELECT-BEYOND Phase 3 Studies

9:00AM-11:00AM: Abstract Number: 1337

Fatigue Levels Are Not Associated with Inflammatory Activity, but with Subjective Outcomes: Results from a Longitudinal Study of Patients with Rheumatoid Arthritis Initiating bDMARD Therapy

9:00AM-11:00AM: Abstract Number: 1342

Identification of Heterogenous Treatment Response Trajectories to anti-IL6 Receptor Treatment in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1376

Impact of 24- or 26-Week Upadacitinib Monotherapy on Patient-Reported Outcomes in Patients with Moderately to Severely Active Rheumatoid Arthritis and No Prior Use of or an Inadequate Response to Methotrexate: Results from Two Phase 3 Trials

9:00AM-11:00AM: Abstract Number: 1353

Impact of Smartphone Application Based Management in Rheumatoid Arthritis: SMART- RA Study

9:00AM-11:00AM: Abstract Number: 1341

Impact of Tocilizumab on Anxiety and Depression in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1348

Impact of Tofacitinib on the Individual Components of the ACR Composite Score in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of Phase 3 Trials

9:00AM-11:00AM: Abstract Number: 1344

Increased High Molecular Weight Adiponectin and Lean Mass During Tocilizumab Treatment in Patients with Rheumatoid Arthritis: A 12 Month Multicenter Study

9:00AM-11:00AM: Abstract Number: 1338

Joint-specific Responses to Tofacitinib and Methotrexate in Rheumatoid Arthritis: A Post Hoc Analysis of Data from ORAL Start

9:00AM-11:00AM: Abstract Number: 1357

Leptin-adjustment of the Multi-biomarker Disease Activity (MBDA) Score Reduces the Influence of Adiposity

9:00AM-11:00AM: Abstract Number: 1363

Longitudinal Work Transitions in Early Inflammatory Arthritis Patients: Are There Targets for Intervention to Improve Employment?

9:00AM-11:00AM: Abstract Number: 1351

Mortality of Rheumatoid Arthritis Patients, Treated to Target at Low Disease Activity: 17-years Follow-up of the BeSt Cohort

9:00AM-11:00AM: Abstract Number: 1331

No Confirmation of Increased Risk of Idiopathic Facial Nerve Palsy Under Tocilizumab

9:00AM-11:00AM: Abstract Number: 1330

No Difference in Treatment Continuation of Different Biologics in Elderly Patients > 70 Years Compared to Younger Patients ≤ 65 Years

9:00AM-11:00AM: Abstract Number: 1370

Not All Joints Are Equal: Challenge DAS28 System and Identify Factors Leading to a Mismatch Between T2T and HAQ Among RA Patients Through Data Mining from Smart System of Disease Management (SSDM)

9:00AM-11:00AM: Abstract Number: 1368

One Size Fits All : Replacing ESR by γGT in DAS28 Calculation Permits a Dual Evaluation of Joint Activity Together with Cardiovascular Risk

9:00AM-11:00AM: Abstract Number: 1350

Patient Disease Trajectories in Baricitinib-2 Mg-Treated Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs

9:00AM-11:00AM: Abstract Number: 1375

Patient-Reported Outcomes of Upadacitinib versus Adalimumab Use in Patients with Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate: 26-Week Analysis of a Phase 3 Study

9:00AM-11:00AM: Abstract Number: 1334

Patterns of Fatigue in Rheumatoid Arthritis Patients Who Received Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs

9:00AM-11:00AM: Abstract Number: 1340

Patterns of Sustained Remission and Subsequent DMARD Tapering in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 1329

Pooled Safety Analyses from Phase 3 Studies of Filgotinib in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1343

Pop a Pill or Give Myself a Shot? Patient Perspectives of Disease-modifying Anti-rheumatic Drug (DMARD) Choice for Rheumatoid Arthritis (RA)

9:00AM-11:00AM: Abstract Number: 1346

Post-Traumatic Stress Disorder, Depression, Anxiety and Persistence of Methotrexate and TNF Inhibitors in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1374

Real-World Evidence: Infections Among RA Patients Switching from First Biologic DMARD to Another Treatment in the US

9:00AM-11:00AM: Abstract Number: 1362

Relationship Between Waking Functions and Disease Activity in Rheumatoid Arthritis Patients Analyzed by Wearable Device

9:00AM-11:00AM: Abstract Number: 1339

Risk of Immunotherapy Related Toxicity in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1366

Self-joint Counts by People with Rheumatoid Arthritis: Does a Video Increase Accuracy and Does It Matter?

9:00AM-11:00AM: Abstract Number: 1336

Systematic Literature Review and Meta-Analysis of DAS28 Clinical Response Rates Among Advanced Therapies in Biologic-Naïve Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1333

The Comparative Risk of Osteoporotic Fractures Among Patients with Rheumatoid Arthritis Receiving TNF Inhibitors versus Other Biologics: A Nation-wide Cohort Study in Korea

9:00AM-11:00AM: Abstract Number: 1328

The Patient’s Perspective on a Disease Flare During Tapering of DMARDs in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1335

Tumor Necrosis Factor Alpha Inhibitor (TNF-α Inhibitor) Exposure and Risk of Hip Fracture in Veterans with Rheumatoid Arthritis: A Nested Case Control Study

9:00AM-11:00AM: Abstract Number: 1360

Ultrasound Guided Synovial Biopsies Safely Aid in the Assessment of Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 1332

United States Rheumatology Practice-Based Real-World Evidence of Infusion Reactions in Rheumatoid Arthritis Patients Treated with Intravenous Golimumab or Infliximab: Impact of Prior Biologic Exposure and Methotrexate Utilization

9:00AM-11:00AM: Abstract Number: 1361

Utility of Rheumatoid Arthritis Impact of Disease (RAID) in Routine Care; Identification of Patients Achieving DAS28 Remission or Low Disease Activity, and Burden of Unmet Patient Reported Outcomes

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].